Select a Region North America

洞察

Insights From Our Experts

Articles

Access Challenges for Severe Infectious Diseases

Content for this article was provided by EVERSANA’s Asia Pacific team. The global burden of infectious diseases is increasing, especially for severe diseases such as invasive aspergillosis, a rare infectious disease, which has a 90% mortality…

Ready or Not, Biosimilar Adalimumab Brings the Heat in 2023

Anticipated Growth in U.S. Biosimilars Market U.S. payers and other healthcare stakeholders have eagerly awaited the launch of biosimilar alternatives to high-cost originator products as a new cost-control lever. However, much of the U.S. healthcare market…

Case Study: Benchmarking Pathway-Specific Engagement with Health Plans & Organized Providers to Identify Best Practices

Tapping into primary market research and subject matter expertise can help uncover opportunities to more effectively meet their needs and position your brand for inclusion within their pathways.  As stakeholders seek to leverage oncology clinical pathways…

Establishing the Patient Access Mission During Clinical Development

An inescapable but disappointing characteristic of pharmaceutical research and development is that at the end of a process costing billions of dollars, the majority of launches fail to reach expectations. The ultimate tragedy of this is…

Regulatory Framework for Digital Therapeutics in the APAC Region

Authored by: Martin Culjat, Kory Dillman, Deval Patel, Rohit Kumar Digital health and digital therapeutics innovation, commercialization, and adoption is accelerating in the APAC region, and this has been in full display at the first-ever DTx…

Maximize In-Licensing Growth

In-licensing is a significant growth lever for a variety of reasons, including: Serving as a risk mitigation tool Reinforce a company’s therapeutic area footprint Serving as a growth catalyst channel to further diversify your pipeline and…

EVERSANA™ COMPLETE Commercialization – Executing on 4 Key Performance Indicators

EVERSANA’s Rohit Sood, Executive Vice President, COMPLETE Commercialization shares the four key performance indicators we focus on with every EVERSANA COMPLETE Commercialization program – Speed, Agility, Consistency and Risk Management.   Check out our whitepaper, CHALLENGING TRADITION:…

Payer Oncology Access Management in 2022

Payers balance the severity of disease with the need to control high-dollar utilization. As pharmacy spend continues to rise, payers are seeking ways to manage costs in the highest cost therapeutic areas, including oncology. While there is appetite…

Emerging Trends in the APAC MedTech Market

Content for this article was contributed by EVERSANA’s Asia Pacific team. APAC’s MedTech market will soon be the second largest in the world. This growth presents both opportunities and challenges across the region. Booming APAC MedTech…

Challenges (and Solutions) to Rapid Omnichannel Transformation

Omnichannel can offer countless benefits and notably improve provider and patient journeys. But current marketplace challenges are disrupting success with omnichannel efforts for some manufacturers, and hindering their quality of service to healthcare professionals and the…